Indivior plc (GB:INDV) has released an update.
Indivior PLC reported a robust start to 2024 with a 12% increase in Q1 net revenue, reaching $284 million, driven largely by the performance of their opioid use disorder treatment, SUBLOCADE. Despite facing transient challenges such as Medicaid disenrollments and a cyberattack on a major medical claims processor, the company reaffirmed its full-year guidance, expecting revenue and profit acceleration as the year progresses. Indivior also announced plans to pursue a primary listing in the U.S. while maintaining a secondary listing in the U.K., reflecting the company’s strategic focus and shareholder base.
For further insights into GB:INDV stock, check out TipRanks’ Stock Analysis page.
